Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs
about
Zinc-mediated Allosteric Inhibition of Caspase-6Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activitySmall-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse ChemotherapeuticsParallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1)Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cellsRemoval of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved PharmacokineticsDerivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosisSM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.Discovery of hybrid dual N-acylhydrazone and diaryl urea derivatives as potent antitumor agents: design, synthesis and cytotoxicity evaluation.Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.
P2860
Q27671521-F9C6CC97-623C-4632-9060-F6630FC127A9Q28304985-021D8AFD-72BA-4C1F-BA15-BF33D5917C6EQ29027136-B6A20867-DAE1-4E5B-855F-04B39D8462A7Q34050598-BD521E7C-EE59-4869-AEF9-133CC89AACCCQ34455521-0A53EB1E-65FD-4B76-B74B-61BF0404EA3EQ35598226-D68E5B3A-9682-4E47-8889-643B8E780FE5Q35859325-5BCB571C-B38A-45AE-BDCB-AA9B6FF3417EQ35946431-A8B27986-AEFD-40B2-ABD0-A3757DC64160Q35995093-2F1BBF3D-ED4B-4369-BA7E-5798AF825C2AQ38753997-5ED84A7C-94B5-44D2-89BF-D4A0822AE74AQ38764663-F8971009-C28A-4D71-B9DA-2CD77EC5564EQ39185552-4BDC8DCB-E849-4BB8-AAFA-5CF796D9F931Q46549141-1030917F-87DB-4865-8F88-1FEE8982C066
P2860
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@ast
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@en
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@nl
type
label
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@ast
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@en
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@nl
prefLabel
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@ast
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@en
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@nl
P2093
P2860
P3181
P1476
Pharmacokinetics and derivatio ...... procaspase-3, in healthy dogs
@en
P2093
Chris J Novotny
Daniel R Doerge
Danny C Hsu
Diana C West
Joanna M Schmit
Laura D Garrett
Levent Dirikolu
Mona I Churchwell
Pamela W Lucas
Paul J Hergenrother
P2860
P2888
P304
P3181
P356
10.1007/S10637-010-9445-Z
P407
P577
2010-05-25T00:00:00Z
P5875
P6179
1038720780